latest news


April 2017 – APP advises consortium on Stada

Funds advised by Bain Capital Private Equity, LP (“Bain Capital”) and by Cinven Partners LLP (“Cinven”), announced the intention to launch a voluntary public takeover offer (the “Takeover Offer”) for all outstanding shares of STADA Arzneimittel AG (“STADA” or the “Company”).

STADA is a leading, independent pharmaceutical company listed on the Frankfurt Stock Exchange. The Company offers a comprehensive portfolio of high-quality, low-cost generic products including selected biosimilars. STADA has also built an attractive portfolio of well-established branded products, including the cold medicine Grippostad® and the Ladival® range of sun protection products.

APP conducted the commercial and product due diligence and advised on all industry aspects of the transaction.


March 2017 – Sean Bowler joins APP

We are delighted to announce that Sean Bowler joins APP as Partner. Sean is an engineer who has been Head of Global Engineering and HSE in several major pharmaceutical companies. He has successfully developed and managed corporate systems in areas such as capital management, project and program delivery, asset life cycle management, network optimization, people development in technical roles and safety performance.


August 2016 – Claudio Albrecht gets appointed as non-executive director of Ino Holdco

Ino Holdco S.A.R.L appointed Claudio Albrecht as non-executive Director. Ino Holdco is an entity controlled by APAX Partners and is the holding company of Neuraxpharm, Germany and Invent Farma, Spain. APP was already advising APAX during the due diligence for both entities.


July 2016 – APP advises a leading PE house on the acquisition of a specialty generic company in Germany

APP was appointed to act as an industry advisor to a leading PE house for the acquisition of a mid sized specialty generic company focused on CNS in Germany. The company acquired is a leading player in CNS. Despite a broad generic Portfolio and Pipeline the company is focused on differentiated products tailored to the concerned target group. APP identified this opportunity, conducted the commercial and product due diligence and advised on all industry aspects of the transaction.


June 2016 – APP advises leading Middle East pharmaceutical player in establishing an Oncology JV

APP was appointed by a leading Middle East pharmaceutical company to advise them on creating an Oncology business in Iran. The project included product selection, development of a business plan, partner search, establishing of a JV structure and advise on the factory layout. The JV was established in June and the construction works for the new facility are starting right away. It is assumed that first products will be launched out of this new facility as early as 2018. Because we believe in this project, APP will hold a minority share in the newly formed JV.


June 2016 – APP advises a leading PE house on the acquisition of a boutique generic company

APP was appointed to act as an industry advisor to a leading PE house for the acquisition of a mid sized boutique generic company. The company acquired is a player in the field of Active Pharmaceutical ingredients,  runs a business to business franchise for finished dosage forms and operates a commercial front end. APP conducted the commercial and product due diligence and advised on all industry aspects of the transaction.


February 2016 – Claudio Albrecht speaks at the world generic congress in Barcelona

Claudio Albrecht, co-founder of APP, was invited as a key note speaker at the world generic congress in Barcelona 2016. The topic of his speech was the M&A activity in the generics industry. Scientific progress will force generics to spend more money for R&D and Sales and Marketing. Product categories like Biosimilars, Immunotherapies or Genetherapies paired with developments in digital health require much more investment than classic commodity generics. This will foster further consolidation among small and mid sized generic companies – Claudio Albrecht said.


January 2016 – Jeff Rope joins APP as Senior Partner

We are delighted to announce that Jeff Rope joins APP as Senior Partner. Jeff Rope served as Global Head of Technical Operations for Sandoz and a member of the Sandoz Executive Committee. Jeff was responsible for a network of more than 30 manufacturing sites and external supply organizations supplying more than 160 countries worldwide.

Jeff has over 35 years experience in Pharmaceutical Operations. Previously Jeff was Executive VP Global Operations for Actavis and has held Plant leadership roles in Pfizer Global Manufacturing.


October 2015 – Shyam Rohra joins APP as Senior Partner

We are glad to announce that Shyam Rohra joins APP as Senior Partner. Shyam has served as President Actavis Operations India and Chairman Lotus Labs, Bangalore.  Shyam Rohra also served ratiopharm in India as its CEO and Managing Director and before that as General Manager of Schweizerhall in India and held several managerial roles at Lupin Labs, Boehringer Knoll, Roussel and Warner Lambert’s Indian Subsidiaries.  


In his 35 years service to Indian and International pharma industry Shyam Rohra has built successful teams and organizations from scratch, established new Laboratories, manufacturing facilities, led several cost-saving initiatives, built high quality response back-offices, helped create strategic supply sources


July 2015 – APP advises European Mid Cap generic company in their sales process

APP was appointed to act as sole transaction advisor for a mid cap generic company in their endeavor to sell their business to a leading US player expanding its presence to Europe. APP was organizing the sales process, the Data room, was leading negotiations and was instrumental in the signing and closing process.


June 2015 – Peter Prock gets re-appointed to the board of directors of Polpharma

After assuming on an interim basis the leadership role for Polpharma, Peter was re-appointed to the board of directors of Polpharma. APP is having a longstanding relationship with the privately held CEE-specialist and conducted a series of strategic projects for Polpharma in the field of Biosimilars, process re-engineering, repositioning of Polpharmas B2B business and other strategic initiatives.